

Human Botulism Immune Globulin for the Treatment o

New England Journal of Medicine

354, 462-471

DOI: 10.1056/nejmoa051926

Citation Report

#	ARTICLE	IF	CITATIONS
1	The Use of Small Molecules to Investigate Molecular Mechanisms and Therapeutic Targets for Treatment of Botulinum Neurotoxin A Intoxication. ACS Chemical Biology, 2006, 1, 359-369.	3.4	41
2	Botulinum type A toxin neutralisation by specific IgG and its fragments: A comparison of mouse systemic toxicity and local flaccid paralysis assays. Toxicon, 2006, 48, 246-254.	1.6	30
3	What's new in the other general journals. BMJ: British Medical Journal, 2006, 332, 351-352.	2.3	0
4	Botulism Rare, but deadly. JAAPA: Official Journal of the American Academy of Physician Assistants, 2006, 19, 41-45.	0.3	2
5	What's new in the other general journals. BMJ: British Medical Journal, 2006, 332, 289-290.	2.3	1
6	Promising Oral Therapy for Pulmonary Hypertension. AAP Grand Rounds, 2006, 15, 41-42.	0.0	0
7	Immune Globulin for Infant Botulism. AAP Grand Rounds, 2006, 15, 42-43.	0.0	0
8	Other articles noted. Evidence-Based Medicine, 2006, 11, 95-96.	0.6	0
9	Adopting Orphan Drugs â€” Two Dozen Years of Treating Rare Diseases. New England Journal of Medicine, 2006, 354, 445-447.	27.0	139
10	An Initial Assessment of the Systemic Pharmacokinetics of Botulinum Toxin. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 1343-1351.	2.5	86
11	Infant Botulism: A 30-Year Experience Spanning the Introduction of Botulism Immune Globulin Intravenous in the Intensive Care Unit at Childrens Hospital Los Angeles. Pediatrics, 2007, 120, e1380-e1385.	2.1	63
12	Investigating novel therapeutic targets and molecular mechanisms to treat botulinum neurotoxin A intoxication. Future Microbiology, 2007, 2, 677-687.	2.0	4
13	Infant Botulism: 20 Years' Experience at a Single Institution. Journal of Child Neurology, 2007, 22, 1333-1337.	1.4	38
14	Neuromuscular junction in health and disease. British Journal of Anaesthesia, 2007, 99, 132-138.	3.4	89
15	Clinical Mimics of Infant Botulism. Pediatrics, 2007, 119, 826-828.	2.1	65
16	Creation and Development of the Public Service Orphan Drug Human Botulism Immune Globulin. Pediatrics, 2007, 119, 785-789.	2.1	57
18	Infant Botulism Presenting With Poor Feeding and Lethargy. Pediatric Emergency Care, 2007, 23, 492-494.	0.9	5
19	Infant Botulism and Treatment With BIG-IV (BabyBIG®). Pediatric Infectious Disease Journal, 2007, 26, 261-262.	2.0	29

#	ARTICLE	IF	CITATIONS
20	Nurse Staffing, Mortality, and Length of Stay in For-Profit and Not-for-Profit Hospitals. Inquiry (United States), 2007, 44, 167-186.	0.9	19
21	Human Botulism Immune Globulin for the Treatment of Infant Botulism. Yearbook of Pediatrics, 2007, 2007, 242-243.	0.2	0
22	An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 2602-2607.	7.1	119
24	Botulism Diagnostics: From Clinical Symptoms to in vitro Assays. Critical Reviews in Microbiology, 2007, 33, 109-125.	6.1	113
25	Chemical Terrorism Attacks: Update on Antidotes. Emergency Medicine Clinics of North America, 2007, 25, 567-595.	1.2	36
26	Food Poisoning. Emergency Medicine Clinics of North America, 2007, 25, 357-373.	1.2	25
28	High-throughput homogeneous immunoassay readily identifies monoclonal antibody to serovariable clostridial neurotoxins. Journal of Immunological Methods, 2007, 328, 128-138.	1.4	10
30	Neurological infections: clinical advances and emerging threats. Lancet Neurology, The, 2007, 6, 16-18.	10.2	5
31	Neuromuscular disorders: therapeutic advances. Lancet Neurology, The, 2007, 6, 18-19.	10.2	1
32	Intestinal toxemia botulism in Italy, 1984-2005. European Journal of Clinical Microbiology and Infectious Diseases, 2007, 26, 385-394.	2.9	45
33	The Strange Case of the Botulinum Neurotoxin: Using Chemistry and Biology to Modulate the Most Deadly Poison. Angewandte Chemie - International Edition, 2008, 47, 8360-8379.	13.8	66
36	Antibodies for the treatment of bacterial infections: current experience and future prospects. Current Opinion in Biotechnology, 2008, 19, 613-619.	6.6	80
37	The biology and future prospects of antivirulence therapies. Nature Reviews Microbiology, 2008, 6, 17-27.	28.6	697
38	Neuromuscular Emergencies. Clinical Pediatric Emergency Medicine, 2008, 9, 88-95.	0.4	5
41	The Neurological Manifestations of Pediatric Infectious Diseases and Immunodeficiency Syndromes. , 2008, , .		1
42	Overconfidence as a Cause of Diagnostic Error in Medicine. American Journal of Medicine, 2008, 121, S2-S23.	1.5	704
43	Infant Botulism Type Ba: First Culture-Confirmed Case in the United Arab Emirates. Pediatric Neurology, 2008, 39, 204-206.	2.1	5
44	Attomolar Detection of Botulinum Toxin Type A in Complex Biological Matrices. PLoS ONE, 2008, 3, e2041.	2.5	100

#	ARTICLE	IF	CITATIONS
46	Biological Terrorism. Infectious Disease Clinics of North America, 2008, 22, 145-187.	5.1	25
47	Global Occurrence of Infant Botulism, 1976-2006. Pediatrics, 2008, 122, e73-e82.	2.1	128
48	Chapter 11 Botulism. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 91, 333-368.	1.8	109
49	Characterization of New Formalin-Detoxified Botulinum Neurotoxin Toxoids. Vaccine Journal, 2008, 15, 1374-1379.	3.1	31
50	Analysis of epitope information related to <i>Bacillus anthracis</i> and <i>Clostridium botulinum</i> . Expert Review of Vaccines, 2008, 7, 55-74.	4.4	26
52	Subunit Vaccine against the Seven Serotypes of Botulism. Infection and Immunity, 2008, 76, 1314-1318.	2.2	105
53	BIG Babies Do Better with Infant Botulism. AAP Grand Rounds, 2008, 19, 30-31.	0.0	0
54	Infant Botulism: Two Recent Cases and Literature Review. Journal of Child Neurology, 2008, 23, 1336-1346.	1.4	34
56	Infant Botulism: a network to improve the diagnosis and treatment of a rare and under-diagnosed disease. Emergency Care Journal, 2008, 4, 35.	0.3	0
57	Biological Events. , 0, , 454-476.		2
58	Botulismo infantil: Comunicaci3n de un caso cl3nico y revisi3n de la literatura. Revista Chilena De Infectologia, 2009, 26, .	0.1	3
60	The Hypotonic Infant. , 2009, , 153-176.		1
61	Index of Suspicion in the Nursery. NeoReviews, 2009, 10, e198-e200.	0.8	0
62	Report of two unlinked cases of infant botulism in the UK in October 2007. Journal of Medical Microbiology, 2009, 58, 1601-1606.	1.8	16
63	Infantile Botulism: Clinical Manifestations, Treatment, and the Role of the Nurse Practitioner. Journal for Nurse Practitioners, 2009, 5, 335-343.	0.8	2
64	A systematic review of the reporting of Data Monitoring Committees' roles, interim analysis and early termination in pediatric clinical trials. BMC Pediatrics, 2009, 9, 77.	1.7	20
65	Accelerating botulism therapeutic product development in the Department of Defense. Drug Development Research, 2009, 70, 303-326.	2.9	4
66	TCEP treatment reduces proteolytic activity of BoNT/B in human neuronal SHSY5Y cells. Journal of Cellular Biochemistry, 2009, 107, 1021-1030.	2.6	17

#	ARTICLE	IF	CITATIONS
68	Cell entry strategy of clostridial neurotoxins. Journal of Neurochemistry, 2009, 109, 1584-1595.	3.9	175
69	Selection and characterization of a human monoclonal neutralizing antibody for Clostridium Botulinum neurotoxin serotype B. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 662-664.	2.2	10
71	Infant botulism mimicking Hirschprung's disease. Journal of Pediatric Surgery, 2009, 44, e5-e7.	1.6	6
72	Biology and Genomic Analysis of Clostridium botulinum. Advances in Microbial Physiology, 2009, 55, 183-320.	2.4	209
74	Special Editorial – 'Menace or the Ultimate Medicine – a case for botulinum neuromedicine'. Botulinum Journal, 2009, 1, 257.	0.2	1
75	Index of Suspicion in the Nursery. NeoReviews, 2009, 10, e36-e38.	0.8	0
77	Universal and specific quantitative detection of botulinum neurotoxin genes. BMC Microbiology, 2010, 10, 267.	3.3	29
79	Convalescent transfusion for pandemic influenza: preparing blood banks for a new plasma product?. Transfusion, 2010, 50, 1384-1398.	1.6	42
80	Infant botulism in Australia: availability of human botulinum antitoxin for treatment. Medical Journal of Australia, 2010, 193, 614-615.	1.7	10
81	First Report Worldwide of an Infant Botulism Case Due to <i>Clostridium botulinum</i> Type E. Journal of Clinical Microbiology, 2010, 48, 326-328.	3.9	31
82	Treatment with Monoclonal Antibodies against<i>Clostridium difficile</i>Toxins. New England Journal of Medicine, 2010, 362, 1444-1446.	27.0	7
83	Type E botulism. Clinical Toxicology, 2010, 48, 880-895.	1.9	42
84	Toxin-mediated syndromes of the nervous system. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2010, 96, 257-272.	1.8	3
85	Identification of a Natural Product Antagonist against the Botulinum Neurotoxin Light Chain Protease. ACS Medicinal Chemistry Letters, 2010, 1, 268-272.	2.8	40
86	A Single-Domain Llama Antibody Potently Inhibits the Enzymatic Activity of Botulinum Neurotoxin by Binding to the Non-Catalytic ±-Exosite Binding Region. Journal of Molecular Biology, 2010, 397, 1106-1118.	4.2	78
87	Paralytic Syndromes in Children: Epidemiology and Relationship to Vaccination. Pediatric Neurology, 2010, 42, 206-212.	2.1	10
88	Botulinum neurotoxin neutralizing activity of immune globulin (IG) purified from clinical volunteers vaccinated with recombinant botulinum vaccine (rBV A/B). Vaccine, 2010, 28, 7313-7318.	3.8	26
89	Therapeutic Use of Immunoglobulins. Advances in Pediatrics, 2010, 57, 185-218.	1.4	25

#	ARTICLE	IF	CITATIONS
91	TÃ©tanos y botulismo. Medicine, 2010, 10, 3410-3417.	0.0	0
92	Treatment and Management of Disorders of the Neuromuscular Junction. , 2011, , 307-342.		2
93	Prevention of Fetal and Early Life Infections Through Maternalâ€œNeonatal Immunization. , 2011, , 1212-1230.		6
94	Acute Neuromuscular Diseases and Disorders. , 2011, , 907-917.		0
95	Forensic Aspects of Biological Toxins. , 2011, , 327-353.		2
96	Enhanced Neutralization Potency of Botulinum Neurotoxin Antibodies Using a Red Blood Cell-Targeting Fusion Protein. PLoS ONE, 2011, 6, e17491.	2.5	11
97	Medical treatment for botulism. , 2011, , CD008123.		17
99	Epitope Characterization of Sero-Specific Monoclonal Antibody to Clostridium botulinum Neurotoxin Type A. Hybridoma, 2011, 30, 503-510.	0.4	3
100	Clinical Reasoning: An unexpected diagnosis in a 4-month-old infant with lethargy and H1N1 influenza. Neurology, 2011, 76, e88-92.	1.1	0
101	Equine Botulinum Antitoxin for the Treatment of Infant Botulism. Vaccine Journal, 2011, 18, 1845-1849.	3.1	27
102	Fatal Course of Foodborne Botulism in an Eighth-Month Old Infant. Mental Illness, 2011, 3, e31.	0.8	6
103	Botulinum Neurotoxins and Botulism: A Novel Therapeutic Approach. Toxins, 2011, 3, 469-488.	3.4	25
104	Identification of the Factors That Govern the Ability of Therapeutic Antibodies to Provide Postchallenge Protection Against Botulinum Toxin: A Model for Assessing Postchallenge Efficacy of Medical Countermeasures against Agents of Bioterrorism and Biological Warfare. Journal of Pharmacology and Experimental Therapeutics, 2011, 338, 503-517.	2.5	18
105	A Bioanalytical Platform for Simultaneous Detection and Quantification of Biological Toxins. Sensors, 2012, 12, 2324-2339.	3.8	32
106	Constipation and poor feeding in an infant with botulism. Cmaj, 2012, 184, 1919-1922.	2.0	9
107	Infant botulism and botulism immune globulin in the UK: a case series of four infants. Archives of Disease in Childhood, 2012, 97, 459-460.	1.9	12
108	Advances in Development of Countermeasures for Potential Biothreat Agents. Advances in Preventive Medicine, 2012, 2012, 1-2.	2.7	0
109	Advanced Development of the rF1V and rBV A/B Vaccines: Progress and Challenges. Advances in Preventive Medicine, 2012, 2012, 1-14.	2.7	30

#	ARTICLE	IF	CITATIONS
110	Identification of Anti-Alpha Toxin Monoclonal Antibodies That Reduce the Severity of Staphylococcus aureus Dermonecrosis and Exhibit a Correlation between Affinity and Potency. Vaccine Journal, 2012, 19, 377-385.	3.1	108
111	Preclinical safety assessment of recombinant botulinum vaccine A/B (rBV A/B). Vaccine, 2012, 30, 1917-1926.	3.8	20
112	New equine antitoxins to botulinum neurotoxins serotypes A and B. Biologicals, 2012, 40, 240-246.	1.4	14
113	Characterization of neutralizing mouse-human chimeric and shuffling antibodies against botulinum neurotoxin A. Microbiology and Immunology, 2012, 56, 748-755.	1.4	4
114	B2M. , 2012, , 281-281.		0
115	Neonatal Hypotonia and Neuromuscular Disorders. , 2012, , 237-261.		0
117	Two cases of type A infant botulism in Grenoble, France: no honey for infants. European Journal of Pediatrics, 2012, 171, 589-591.	2.7	11
118	The Hypotonic Infant. , 2013, , 147-169.		1
119	Differences in immunological responses of polyclonal botulinum A1 and A2 antitoxin against A1 and A2 toxin. Toxicon, 2013, 73, 9-16.	1.6	9
120	The life history of a botulinum toxin molecule. Toxicon, 2013, 68, 40-59.	1.6	113
121	Passive immunization. , 2013, , 80-87.		2
122	Biodefense and special pathogen vaccines. , 2013, , 1008-1017.		1
123	Efficacy of Clostridium botulinum types C and D toxoid vaccination in Danish cows. Anaerobe, 2013, 23, 97-101.	2.1	30
124	Infant botulism: First two confirmed cases in Slovenia and literature review. European Journal of Paediatric Neurology, 2013, 17, 651-656.	1.6	5
125	DNA electroporation in rabbits as a method for generation of high-titer neutralizing antisera. Human Vaccines and Immunotherapeutics, 2013, 9, 2147-2156.	3.3	4
126	Of war and sausages: A case-directed review of infant botulism. Journal of Paediatrics and Child Health, 2013, 49, E232-4.	0.8	6
127	Ten-Week-Old Girl With Lethargy, Weakness, and Poor Feeding. Clinical Pediatrics, 2013, 52, 190-193.	0.8	1
128	The challenges of foodborne pathogens and antimicrobial chemotherapy: A global perspective. African Journal of Microbiology Research, 2013, 7, 1158-1172.	0.4	21

#	ARTICLE	IF	CITATIONS
129	Production of a Neutralizing Mouse-Human Chimeric Antibody against Botulinum Neurotoxin Serotype E. Japanese Journal of Infectious Diseases, 2013, 66, 46-50.	1.2	2
131	Mechanical ventilation and management of an adult horse with presumptive botulism. Journal of Veterinary Emergency and Critical Care, 2014, 24, 594-601.	1.1	6
132	Infant Botulism and Indications for Administration of Botulism Immune Globulin. Pediatric Emergency Care, 2014, 30, 120-124.	0.9	17
133	“Infantile botulism: Forgotten etiology of acute hypotonia in infancy”, Pediatric Infectious Disease, 2014, 6, 132-134.	0.1	0
134	New targets in the search for preventive and therapeutic agents for botulism. Expert Review of Anti-Infective Therapy, 2014, 12, 1075-1086.	4.4	11
135	Molecular Epidemiology of Infant Botulism in California and Elsewhere, 1976–2010. Journal of Infectious Diseases, 2014, 210, 1711-1722.	4.0	28
136	Hypotonic Infant. , 2014, , 661-665.		0
137	Neuromuscular Complications of General Medical Disorders. , 2014, , 1209-1242.		0
138	A Novel Strain of Clostridium botulinum That Produces Type B and Type H Botulinum Toxins. Journal of Infectious Diseases, 2014, 209, 183-191.	4.0	289
139	Issues associated with formula milk: the Hong Kong’s experience. World Journal of Pediatrics, 2014, 10, 5-6.	1.8	1
141	Medical treatment for botulism. The Cochrane Library, 2014, , CD008123.	2.8	33
142	Acute Pediatric Neurology. , 2014, , .		0
143	Infant Botulism: Is There an Association With Thiamine Deficiency?. Pediatrics, 2014, 134, e1436-e1440.	2.1	13
144	Botulinum neurotoxins: genetic, structural and mechanistic insights. Nature Reviews Microbiology, 2014, 12, 535-549.	28.6	461
145	Safety and Pharmacokinetics of XOMA 3AB, a Novel Mixture of Three Monoclonal Antibodies against Botulinum Toxin A. Antimicrobial Agents and Chemotherapy, 2014, 58, 5047-5053.	3.2	50
146	A Platform Stratifying a Sequestering Agent and a Pharmacological Antagonist as a Means to Negate Botulinum Neurotoxicity. ACS Chemical Neuroscience, 2014, 5, 632-636.	3.5	4
147	Humanized Staphylococcal Enterotoxin B (SEB)–Specific Monoclonal Antibodies Protect From SEB Intoxication and Staphylococcus aureus Infections Alone or as Adjunctive Therapy With Vancomycin. Journal of Infectious Diseases, 2014, 210, 973-981.	4.0	32
148	Infant botulism in Andalusia (Southern Spain). European Journal of Paediatric Neurology, 2014, 18, 321-326.	1.6	6

#	ARTICLE	IF	CITATIONS
150	Infant botulism manifesting in an exclusively breast-fed patient: A case report. <i>Journal of Pediatric Neurology</i> , 2015, 09, 383-386.	0.2	0
151	Relationship between the incidence of infant botulism and the presence of botulinum-toxin producing clostridia in the soil of Argentina from 1982â€“2005. <i>Journal of Pediatric Neurology</i> , 2015, 05, 279-286.	0.2	7
153	Stimulated jitter analysis in the early diagnosis of infant botulism. <i>Muscle and Nerve</i> , 2015, 52, 309-310.	2.2	4
154	Isolation of nanomolar scFvs of non-human primate origin, cross-neutralizing botulinum neurotoxins A1 and A2 by targeting their heavy chain. <i>BMC Biotechnology</i> , 2015, 15, 86.	3.3	9
155	Botulism (<i>Clostridium botulinum</i>). , 2015, , 2763-2767.e2.		7
156	Monoclonal Antibodies that Inhibit the Proteolytic Activity of Botulinum Neurotoxin Serotype/B. <i>Toxins</i> , 2015, 7, 3405-3423.	3.4	18
157	Abnormal Neuroimaging in a Case of Infant Botulism. <i>Frontiers in Pediatrics</i> , 2015, 3, 108.	1.9	1
158	Development of Human-Like scFv-Fc Neutralizing Botulinum Neurotoxin E. <i>PLoS ONE</i> , 2015, 10, e0139905.	2.5	21
160	Spotting infantile botulism: a taste of molten honey. <i>Paediatrics and Child Health (United Kingdom)</i> , 2015, 25, 332-334.	0.4	2
162	ExÂvivo inhibition of <i>Clostridium botulinum</i> neurotoxin types B, C, E, and F by small molecular weight inhibitors. <i>Toxicon</i> , 2015, 98, 12-19.	1.6	10
163	Anti-virulence Strategies to Target Bacterial Infections. <i>Current Topics in Microbiology and Immunology</i> , 2015, 398, 147-183.	1.1	141
164	Presynaptic Disorders: Lambert-Eaton Myasthenic Syndrome and Botulism. <i>Seminars in Neurology</i> , 2015, 35, 340-346.	1.4	3
165	<i>Clostridium botulinum</i> and Associated Neurotoxins. , 2015, , 1015-1029.		0
166	Genomic sequences of six botulinum neurotoxin-producing strains representing three clostridial species illustrate the mobility and diversity of botulinum neurotoxin genes. <i>Infection, Genetics and Evolution</i> , 2015, 30, 102-113.	2.3	70
167	Infant Botulism: Review and Clinical Update. <i>Pediatric Neurology</i> , 2015, 52, 487-492.	2.1	88
168	The Biosecurity Threat Posed by Biological Toxins. <i>Toxinology</i> , 2015, , 141-183.	0.2	1
169	Diffuse Muscle Weakness in an Infant. <i>Clinical Pediatrics</i> , 2015, 54, 1394-1395.	0.8	1
170	The Per Case and Total Annual Costs of Foodborne Illness in the United States. <i>Risk Analysis</i> , 2015, 35, 1125-1139.	2.7	76

#	ARTICLE	IF	CITATIONS
171	Infant botulism due to <i>C. butyricum</i> type E toxin: a novel environmental association with pet terrapins. <i>Epidemiology and Infection</i> , 2015, 143, 461-469.	2.1	25
172	Botulinum neurotoxin: Progress in negating its neurotoxicity; and in extending its therapeutic utility via molecular engineering. <i>MiniReview. Peptides</i> , 2015, 72, 80-87.	2.4	5
173	The Expanding Role of Therapeutic Antibodies. <i>International Reviews of Immunology</i> , 2015, 34, 202-264.	3.3	22
174	Development of human-like scFv-Fc antibodies neutralizing Botulinum toxin serotype B. <i>MAbs</i> , 2015, 7, 1161-1177.	5.2	25
175	Genomic Epidemiology of <i>Clostridium botulinum</i> Isolates from Temporally Related Cases of Infant Botulism in New South Wales, Australia. <i>Journal of Clinical Microbiology</i> , 2015, 53, 2846-2853.	3.9	9
176	Antibacterial monoclonal antibodies: the next generation?. <i>Current Opinion in Microbiology</i> , 2015, 27, 78-85.	5.1	77
177	Centrifugal Microfluidic Platform for Ultrasensitive Detection of Botulinum Toxin. <i>Analytical Chemistry</i> , 2015, 87, 922-928.	6.5	63
178	Targeting virulence not viability in the search for future antibacterials. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 208-215.	2.4	144
179	Algal chloroplast produced camelid ν H antitoxins are capable of neutralizing botulinum neurotoxin. <i>Plant Biotechnology Journal</i> , 2015, 13, 117-124.	8.3	40
180	Botulinum Toxin-Clostridium Botulinum. , 2016, , 16.5.1-16.5.9.		0
181	Clostridium botulinum Toxin (Botulism) Attack. , 2016, , 790-793.		1
183	Bacterial Spores and its Relatives as Agents of Mass Destruction. <i>Journal of Bioterrorism & Biodefense</i> , 2016, 07, .	0.1	7
184	Neutralization of Botulinum Neurotoxin Type E by a Humanized Antibody. <i>Toxins</i> , 2016, 8, 257.	3.4	12
186	Botulism. <i>Pediatrics in Review</i> , 2016, 37, 183-192.	0.4	42
187	Case 1: Constipation, Irritability, and Poor Feeding in 2-month-old Boy. <i>Pediatrics in Review</i> , 2016, 37, 391-393.	0.4	0
189	Biological Events. , 0, , 522-543.		0
190	A case of infant botulism in a 4-month-old baby. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2016, 109, 47-48.	0.5	2
191	Purification and Characterization of Botulinum Neurotoxin FA from a Genetically Modified <i>Clostridium botulinum</i> Strain. <i>MSphere</i> , 2016, 1, .	2.9	44

#	ARTICLE	IF	CITATIONS
192	A Novel Botulinum Neurotoxin, Previously Reported as Serotype H, Has a Hybrid-Like Structure With Regions of Similarity to the Structures of Serotypes A and F and Is Neutralized With Serotype A Antitoxin. Journal of Infectious Diseases, 2016, 213, 379-385.	4.0	118
193	Therapies That Manipulate Host Defense Mechanisms. , 2016, , 341-352.		0
194	Early diagnosis and treatment in a child with foodborne botulism. Anaerobe, 2016, 39, 189-192.	2.1	9
195	Trends in Outcomes and Hospitalization Charges of Infant Botulism in the United States: A Comparative Analysis Between Kids' Inpatient Database and National Inpatient Sample. Pediatric Neurology, 2017, 67, 53-58.	2.1	8
196	Chemical Strategies To Target Bacterial Virulence. Chemical Reviews, 2017, 117, 4422-4461.	47.7	100
197	Challenges in searching for therapeutics against Botulinum Neurotoxins. Expert Opinion on Drug Discovery, 2017, 12, 497-510.	5.0	41
198	Use of human immunoglobulins as an anti-infective treatment: the experience so far and their possible re-emerging role. Expert Review of Anti-Infective Therapy, 2017, 15, 585-604.	4.4	28
199	Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance. Nature Reviews Drug Discovery, 2017, 16, 457-471.	46.4	570
201	Effective treatment of infant botulism on day 13 after symptom onset with human botulism antitoxin. Journal of Paediatrics and Child Health, 2017, 53, 416-418.	0.8	3
202	Pediatric Electromyography. , 2017, , .		2
205	Infant Botulism in the Very Young Neonate: A Case Series. AJP Reports, 2017, 07, e163-e166.	0.7	5
206	Use-dependent potentiation of voltage-gated calcium channels rescues neurotransmission in nerve terminals intoxicated by botulinum neurotoxin serotype A. Scientific Reports, 2017, 7, 15862.	3.3	6
207	One-Month-Old Infant With Hypotonia and Cardiorespiratory Arrest. Clinical Pediatrics, 2017, 56, 397-398.	0.8	1
209	Flaccid paralysis in an infant associated with a dirty wound and application of honey. BMJ Case Reports, 2017, 2017, bcr2016218044.	0.5	4
210	Role of Homologous Fc Fragment in the Potency and Efficacy of Anti-Botulinum Antibody Preparations. Toxins, 2017, 9, 180.	3.4	9
211	SiMa Cells for a Serotype Specific and Sensitive Cell-Based Neutralization Test for Botulinum Toxin A and E. Toxins, 2017, 9, 230.	3.4	8
212	The European Antibody Framework Program and Its Update: Development of Innovative Botulinum Antibodies. Toxins, 2017, 9, 309.	3.4	30
213	A three monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotype F subtypes. PLoS ONE, 2017, 12, e0174187.	2.5	27

#	ARTICLE	IF	CITATIONS
214	Therapeutic Antibodies for Biodefense. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1053, 173-205.	1.6	7
215	Applying Unconventional Secretion in <i>Ustilago maydis</i> for the Export of Functional Nanobodies. <i>International Journal of Molecular Sciences</i> , 2017, 18, 937.	4.1	25
216	Safety and immunogenicity of investigational recombinant botulinum vaccine, rBV A/B, in volunteers with pre-existing botulinum toxoid immunity. <i>Vaccine</i> , 2018, 36, 2041-2048.	3.8	27
217	High level expression and immunochemical characterization of botulinum neurotoxin type F light chain. <i>Protein Expression and Purification</i> , 2018, 146, 51-60.	1.3	7
218	3,4-diaminopyridine reverses paralysis in botulinum neurotoxin-intoxicated diaphragms through two functionally distinct mechanisms. <i>Toxicology and Applied Pharmacology</i> , 2018, 341, 77-86.	2.8	10
219	<i>Clostridium botulinum</i> (Botulism). , 2018, , 999-1006.e2.		2
220	Yesterday and Today: The Impact of Research Conducted at Camp Detrick on Botulinum Toxin. <i>Military Medicine</i> , 2018, 183, 85-95.	0.8	7
221	Levels Above Lower Motor Neuron to Neuromuscular Junction. , 2018, , 887-921.e11.		0
222	Efficacy of Human Botulism Immune Globulin for the Treatment of Infant Botulism: The First 12 Years Post Licensure. <i>Journal of Pediatrics</i> , 2018, 193, 172-177.	1.8	44
223	More Clinical Mimics of Infant Botulism. <i>Journal of Pediatrics</i> , 2018, 193, 178-182.	1.8	19
224	Efficacy of Antitoxin Therapy in Treating Patients With Foodborne Botulism: A Systematic Review and Meta-analysis of Cases, 1923â€“2016. <i>Clinical Infectious Diseases</i> , 2018, 66, S43-S56.	5.8	50
225	Antibody Therapy. , 2018, , .		0
226	Passive Immunization. , 2018, , 37-43.e2.		0
227	Enteric Diseases Transmitted Through Food, Water, and Zoonotic Exposures. , 2018, , 397-409.e3.		0
228	Anti-Virulence Factor Therapeutics. , 2018, , 439-461.		0
229	Disaster Preparedness: Biological Threats and Treatment Options. <i>Pharmacotherapy</i> , 2018, 38, 217-234.	2.6	30
230	Antimicrobial Susceptibility of 260 <i>Clostridium botulinum</i> Type A, B, Ba, and Bf Strains and a Neurotoxigenic <i>Clostridium baratii</i> Type F Strain Isolated from California Infant Botulism Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	9
231	A Single Tri-Epitopic Antibody Virtually Recapitulates the Potency of a Combination of Three Monoclonal Antibodies in Neutralization of Botulinum Neurotoxin Serotype A. <i>Toxins</i> , 2018, 10, 84.	3.4	8

#	ARTICLE	IF	CITATIONS
232	Type F Infant Botulism: Investigation of Recent Clusters and Overview of This Exceedingly Rare Disease. Clinical Infectious Diseases, 2018, 66, S92-S94.	5.8	6
233	Human Botulism Immune Globulin for Treatment of Infant Botulism. AAP Grand Rounds, 2018, 40, 3-3.	0.0	0
234	Neonatal Hypotonia. NeoReviews, 2018, 19, e445-e455.	0.8	4
235	Pediatric Botulism and Use of Equine Botulinum Antitoxin in Children: A Systematic Review. Clinical Infectious Diseases, 2018, 66, S17-S29.	5.8	15
236	Question 1: In infant botulism, is equine-derived botulinum antitoxin (EqBA) an effective alternative therapy to human-derived botulinum immune globulin (BIG)? Archives of Disease in Childhood, 2018, 103, 907.1-909.	1.9	3
237	A Small Molecule-Screening Pipeline to Evaluate the Therapeutic Potential of 2-Aminoimidazole Molecules Against Clostridium difficile. Frontiers in Microbiology, 2018, 9, 1206.	3.5	17
238	Towards evidence-based medicine for paediatricians. Archives of Disease in Childhood, 2018, 103, 907.2-907.	1.9	0
239	Basics of Immunoglobulins as Effector Molecules and Drugs. , 2018, , 133-150.		0
240	Passive Immunization. , 2018, , 84-95.e10.		20
241	Biodefense and Special Pathogen Vaccines. , 2018, , 149-160.e7.		5
242	Eyelid and Facial Nerve Disorders. , 2019, , 449-488.		2
243	The Hypotonic Infant. , 2019, , 150-171.		0
244	Pharmacokinetics of Human Recombinant Anti-Botulinum Toxin Antibodies in Rats. Toxins, 2019, 11, 345.	3.4	8
245	Neuromuscular Diseases of the Newborn. Seminars in Pediatric Neurology, 2019, 32, 100771.	2.0	6
246	Targeted 8-hydroxyquinoline fragment based small molecule drug discovery against neglected botulinum neurotoxin type F. Bioorganic Chemistry, 2019, 92, 103297.	4.1	4
247	Antibodies and Vaccines Against Botulinum Toxins: Available Measures and Novel Approaches. Toxins, 2019, 11, 528.	3.4	33
248	Monoclonal Antibody Combinations Prevent Serotype A and Serotype B Inhalational Botulism in a Guinea Pig Model. Toxins, 2019, 11, 208.	3.4	18
249	Cryptococcal Meningitis and Anti-virulence Therapeutic Strategies. Frontiers in Microbiology, 2019, 10, 353.	3.5	31

#	ARTICLE	IF	CITATIONS
250	Medical treatment for botulism. The Cochrane Library, 2019, 4, CD008123.	2.8	13
251	Covalent Modifiers of Botulinum Neurotoxin Counteract Toxin Persistence. ACS Chemical Biology, 2019, 14, 76-87.	3.4	11
252	Targeting virulence factors as an antimicrobial approach: Pigment inhibitors. Medicinal Research Reviews, 2020, 40, 293-338.	10.5	18
253	Acute Neuromuscular Disorders in the Pediatric Intensive Care Unit. Journal of Child Neurology, 2020, 35, 17-24.	1.4	12
254	Passive Monoclonal and Polyclonal Antibody Therapies. , 2020, , 251-348.		9
255	BOTOX injection to treat strabismus after infant botulism type B infection. American Journal of Ophthalmology Case Reports, 2020, 20, 100895.	0.7	0
256	Toxemia in Human Naturally Acquired Botulism. Toxins, 2020, 12, 716.	3.4	20
257	Special Delivery: Potential Mechanisms of Botulinum Neurotoxin Uptake and Trafficking within Motor Nerve Terminals. International Journal of Molecular Sciences, 2020, 21, 8715.	4.1	13
258	Seven-Year Case-Control Study in California of Risk Factors for Infant Botulism. Journal of Pediatrics, 2020, 227, 258-267.e8.	1.8	10
259	Characterization of immune response induced against catalytic domain of botulinum neurotoxin type E. Scientific Reports, 2020, 10, 13932.	3.3	1
260	Descriptive Epidemiology of Infant Botulism in California: The First 40 Years. Journal of Pediatrics, 2020, 227, 247-257.e3.	1.8	13
261	Fully Human Monoclonal Antibodies Effectively Neutralizing Botulinum Neurotoxin Serotype B. Toxins, 2020, 12, 302.	3.4	6
262	Case 3: Hypotonia in the Infant: When the Source Is Unknown. Pediatrics in Review, 2020, 41, 145-147.	0.4	0
263	Botulism in the Pediatric Intensive Care Units in the United States: Interrogating a National Database. Journal of Pediatric Intensive Care, 2020, 09, 012-015.	0.8	0
264	Preparation and characterization of folic acid conjugated sulfated polysaccharides on NK cell activation and cellular uptake in HeLa cells. Carbohydrate Polymers, 2021, 254, 117250.	10.2	11
265	Bacteriophages as drivers of bacterial virulence and their potential for biotechnological exploitation. FEMS Microbiology Reviews, 2021, 45, .	8.6	53
266	Clostridium botulinum. , 2021, , 405-416.		0
267	A Monoclonal Antibody Combination against both Serotypes A and B Botulinum Toxin Prevents Inhalational Botulism in a Guinea Pig Model. Toxins, 2021, 13, 31.	3.4	6

#	ARTICLE	IF	CITATIONS
268	Delivery of single-domain antibodies into neurons using a chimeric toxin-based platform is therapeutic in mouse models of botulism. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	33
269	Clinical Predictive Values in Botulism: A 10-year Survey. <i>Indian Journal of Critical Care Medicine</i> , 2021, 25, 411-415.	0.9	3
270	Characterization of a highly neutralizing single monoclonal antibody to botulinum neurotoxin type A. <i>FASEB Journal</i> , 2021, 35, e21540.	0.5	6
271	Polyclonal hyper immunoglobulin: A proven treatment and prophylaxis platform for passive immunization to address existing and emerging diseases. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-20.	3.3	18
272	Infant botulism: an underestimated threat. <i>Infectious Diseases</i> , 2021, 53, 647-660.	2.8	9
273	Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021. <i>MMWR Recommendations and Reports</i> , 2021, 70, 1-30.	61.1	55
274	Safety, Tolerability, and Pharmacokinetics of NTM-1632, a Novel Mixture of Three Monoclonal Antibodies against Botulinum Toxin B. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0232920.	3.2	9
275	A summary of surveillance, morbidity and microbiology of laboratory-confirmed cases of infant botulism in Canada, 1979-2019. <i>Canada Communicable Disease Report</i> , 2021, 47, 322-328.	1.3	6
276	A Novel Running Wheel Mouse Model for Botulism and Its Use for the Evaluation of Postsymptom Antitoxin Efficacy. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0042121.	3.2	3
277	Infections of the Peripheral Nervous System. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2021, 27, 921-942.	0.8	0
278	Neutralizing Concentrations of Anti-Botulinum Toxin Antibodies Positively Correlate with Mouse Neutralization Assay Results in a Guinea Pig Model. <i>Toxins</i> , 2021, 13, 671.	3.4	5
279	Effects of antibiotics on the viability of and toxin production by <i>Clostridium botulinum</i> . <i>Microbiology and Immunology</i> , 2021, 65, 432-437.	1.4	1
280	Treatment and Management of Disorders of the Neuromuscular Junction. , 2022, , 446-491.		1
284	Botulism as a Disease of Humans. , 2014, , 259-289.		4
285	Prevention and Treatment of Botulism. , 2014, , 291-342.		1
286	Control of <i>Clostridium botulinum</i> in Foods. , 2016, , 83-93.		3
288	<i>Clostridium botulinum</i> (Botulism). , 2008, , 959-966.		2
289	Disorders of Neuromuscular Transmission. , 2008, , 2383-2402.		15

#	ARTICLE	IF	CITATIONS
290	Neuromuscular Complications of General Medical Disorders. , 2008, , 1123-1156.		1
291	Neuromuscular Disorders: Levels above the Lower Motor Neuron to the Neuromuscular Junction. , 2008, , 767-800.		3
292	Long-term Effects of Botulinum Toxin on Neuromuscular Function. Anesthesiology, 2007, 106, 1139-1146.	2.5	45
293	Clostridium botulinum. , 0, , 31-52.		6
295	Clostridium. , 0, , 940-966.		7
296	Clostridium botulinum. , 0, , 441-463.		5
297	Persistent neurogenic bladder dysfunction due to infantile botulism. BMJ Case Reports, 2014, 2014, bcr2013202077-bcr2013202077.	0.5	1
298	Symptomatic treatment of botulism with a clinically approved small molecule. JCI Insight, 2020, 5, .	5.0	14
299	Tetanus, Botulism, and Diphtheria. CONTINUUM Lifelong Learning in Neurology, 2018, 24, 1459-1488.	0.8	6
300	A Novel Strategy for Development of Recombinant Antitoxin Therapeutics Tested in a Mouse Botulism Model. PLoS ONE, 2012, 7, e29941.	2.5	77
301	Monoclonal Antibodies Targeting the Alpha-Exosite of Botulinum Neurotoxin Serotype/A Inhibit Catalytic Activity. PLoS ONE, 2015, 10, e0135306.	2.5	15
302	Development of Germline-Humanized Antibodies Neutralizing Botulinum Neurotoxin A and B. PLoS ONE, 2016, 11, e0161446.	2.5	21
303	Therapeutic efficacy of equine botulism antitoxin in Rhesus macaques. PLoS ONE, 2017, 12, e0186892.	2.5	31
304	Identification of Inhibitors against Botulinum Neurotoxins: 8-Hydroxyquinolines Hold Promise. Mini-Reviews in Medicinal Chemistry, 2019, 19, 1694-1706.	2.4	3
305	Cargo-Delivery Platforms for Targeted Delivery of Inhibitor Cargos Against Botulism. Current Topics in Medicinal Chemistry, 2014, 14, 2081-2093.	2.1	7
306	Source of Botulinum Antitoxin Products Needs Clarifying. Pediatric Annals, 2010, 39, 261-262.	0.8	1
307	Botulinum Neurotoxins as Biothreat Agents. Journal of Bioterrorism & Biodefense, 2011, s2, .	0.1	8
308	Anti-virulence Therapy Against Bacterial Infections: Mechanisms of Action and Challenges. Journal of Kermanshah University of Medical Sciences, 2021, 25, .	0.4	1

#	ARTICLE	IF	CITATIONS
309	Trial of Immune Globulin in Infant Botulism. Pediatric Neurology Briefs, 2006, 20, 13.	0.2	0
310	Infant Botulism. , 2007, , 1173-1175.		0
311	Infektionserkrankungen. , 2007, , 439-533.		1
312	Human Botulism Immune Globulin for the Treatment of Infant Botulism. Yearbook of Neurology and Neurosurgery, 2007, 2007, 61-62.	0.0	0
313	Mechanism of Action of Botulinum Neurotoxin and Overview of Medical Countermeasures for Intoxication. , 2007, , .		0
314	Neonatal Hypotonia. , 2008, , 172-194.		0
315	Neuromuskuläre Störungen beim Intensivpatienten, Critical-illness-Neuropathie und andere neurologische Störungen. , 2008, , 695-706.		0
316	Passive Immunization. , 2008, , 41-48.		0
317	Possibility to Obtain Anti-Athrax Human Immunoglobulin for Intravenous Injection. Problemy Osobo Opasnykh Infektsii, 2008, , 39-42.	0.6	0
319	INFANT BOTULISM. , 2009, , 1862-1870.		1
320	PASSIVE IMMUNIZATION. , 2009, , 3401-3446.		2
321	Complex Ocular Motor Disorders in Children. , 2010, , 309-382.		6
323	Eyelid and facial nerve disorders. , 2010, , 449-489.		0
324	The Role of the Physician-Educator is Evolving. Pediatric Annals, 2010, 39, 262-264.	0.8	2
325	Infant Botulism and Raised Intraocular Pressure. Journal of Pediatric Ophthalmology and Strabismus, 2010, 47, 1-3.	0.7	3
326	Sports Safety: Nutrition, Psychology, Overuse, Contact, Strength, and Non-Contact. Pediatric Annals, 2010, 39, 259-260.	0.8	0
328	Infektionskrankheiten und Schutzimpfungen. , 2011, , 967-1113.		0
331	Neuromuskuläre Erkrankungen bei Intensivpatienten. , 2011, , 701-711.		0

#	ARTICLE	IF	CITATIONS
333	Hypotonic (Floppy) Infant. , 2012, , 319-328.		2
334	Disorders of Neuromuscular Transmission. , 2012, , 2046-2065.		0
335	Infant Botulism. , 2012, , 995-996.		0
336	Neuromuskuläre Erkrankungen. , 2012, , 673-714.		0
337	Passive Immunization. , 2012, , 37-44.e3.		0
338	Clostridium botulinum (Botulism). , 2012, , 970-977.e2.		1
339	A Case of Dyspnea Caused by Local Botulinum Toxin Type A Injection. Korean Journal of Medicine, 2013, 84, 851.	0.3	0
342	Clostridien. , 2013, , 291-296.		0
343	Management of Acute Neuromuscular Disorders. , 2014, , 271-286.		0
344	Biosecurity and Toxins. , 2014, , 1-39.		0
345	Enfermedades causadas por toxinas bacterianas: tétanos, botulismo y difteria. , 2014, , 53-63.		0
346	Diseases of the Peripheral Nervous System. , 2014, , 695-710.		2
347	Botulinum Neurotoxin Antidotes. , 2014, , 1-23.		0
348	Basic Chemistry of Botulinum Neurotoxins Relevant to Vaccines, Diagnostics, and Countermeasures. , 2014, , 1-33.		0
349	Neuromuscular diseases in intensive care. , 2014, , 617-626.e3.		0
350	Botulism as a Food Poisoning : What Is It ?. Journal of the Egyptian Society of Parasitology, 2014, 44, 211-220.	0.2	2
351	Neuromuskuläre Erkrankungen bei Intensivpatienten. , 2015, , 623-634.		0
352	Neuromuskuläre Erkrankungen bei Intensivpatienten. , 2015, , 1-20.		0

#	ARTICLE	IF	CITATIONS
353	Antidotes to Botulinum Neurotoxin. Toxinology, 2015, , 375-400.	0.2	1
355	Basic Chemistry of Botulinum Neurotoxins Relevant to Vaccines, Diagnostics, and Countermeasures. Toxinology, 2015, , 469-504.	0.2	1
356	Clostridien-Infektionen. , 2015, , 1-7.		0
357	Neuromuskuläre Erkrankungen. , 2015, , 725-768.		0
358	Complex Ocular Motility Disorders in Children. , 2016, , 393-494.		0
359	Neuromuscular Complications in the Critically Ill Child. , 2017, , 355-369.		0
360	Neuromuscular Junction Disorders. , 2017, , 311-325.		0
362	Clostridium botulinum and the Most Poisonous Poison. , 2017, , 553-601.		2
364	OBSOLETE: Botulism. , 2017, , .		0
366	Clinical Suspicion of Infant Botulism in a Patient Presenting with Generalized Weakness. Journal of the Japanese Association for Infectious Diseases, 2018, 92, 65-70.	0.0	0
368	Neonatal. , 2020, , 147-173.		0
369	Botulism, gas gangrene, and clostridial gastrointestinal infections. , 2020, , 1120-1126.		0
371	Infant botulism in Singapore. Singapore Medical Journal, 2020, 61, 165-166.	0.6	0
372	Clinical cases of atypical and severe botulism. ZaporoÅ¼skij Medicinskij Å½urnal, 2020, .	0.2	0
373	An alternative in vivo method to refine the mouse bioassay for botulinum toxin detection. Comparative Medicine, 2011, 61, 235-42.	1.0	31
375	The Newborn with Neurologic Findings. , 2020, , .		0
376	Light Chain Role in Action of Botulinum Toxins/Clostridial Neurotoxins. , 2021, , 1-10.		0
377	Feeding Intolerance in a 3-month-old. Pediatrics in Review, 2022, 43, 45-48.	0.4	0

#	ARTICLE	IF	CITATIONS
378	Bacterial-fungal interactions and their impact on microbial pathogenesis. <i>Molecular Ecology</i> , 2023, 32, 2565-2581.	3.9	13
379	First-in-Human Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of Single Doses of NTM-1633, a Novel Mixture of Monoclonal Antibodies against Botulinum Toxin E. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0173221.	3.2	6
380	Rapid Onset of Neuromuscular Paralysis or Weakness. <i>Critical Care Clinics</i> , 2022, 38, 413-428.	2.6	1
381	Adult Intestinal Toxemia Botulism in a Patient With Crohn's Disease. <i>ACG Case Reports Journal</i> , 2022, 9, e00718.	0.4	1
382	Infant Botulism: Checklist for Timely Clinical Diagnosis and New Possible Risk Factors Originated from a Case Report and Literature Review. <i>Toxins</i> , 2021, 13, 860.	3.4	4
384	Exposure-Response Modeling and Simulation to Support Human Dosing of Botulism Antitoxin Heptavalent Product. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 171-180.	4.7	1
385	Infant botulism: Report of a misleading case and important key messages. <i>Archives De Pediatrie</i> , 2022, 29, 395-397.	1.0	2
386	Antidotal treatment of botulism in rats by continuous infusion with 3,4-diaminopyridine. <i>Molecular Medicine</i> , 2022, 28, .	4.4	3
387	Next-Generation Approaches Needed to Tackle Antimicrobial Resistance for the Development of Novel Therapies Against the Deadly Pathogens. <i>Frontiers in Pharmacology</i> , 2022, 13, .	3.5	5
388	Acute Onset Descending Paralysis in an Infant Newly Diagnosed With Pneumonia. <i>Clinical Pediatrics</i> , 0, , 000992282211131.	0.8	0
389	Dual-Toxin (â€œBivalentâ€) Infant Botulism in California, 1976-2020: Epidemiologic, Clinical, and Laboratory Aspects. <i>Journal of Pediatrics</i> , 2023, 253, 8-13.	1.8	1
390	Immunologic and Protective Properties of Subunit- vs. Whole Toxoid-Derived Anti-Botulinum Equine Antitoxin. <i>Vaccines</i> , 2022, 10, 1522.	4.4	2
391	Food Safety: Infectious Disease. , 2020, , .		0
392	NeuromuskulÄre Erkrankungen bei Intensivpatienten. <i>Springer Reference Medizin</i> , 2022, , 1-16.	0.0	0
393	<i>Clostridium botulinum</i> (Botulism). , 2023, , 1017-1024.e2.		0
394	Enteric Diseases Transmitted Through Food, Water, and Zoonotic Exposures. , 2023, , 408-418.e3.		0
395	Passive Immunization. , 2023, , 38-44.e2.		0
396	Designing, synthesis and evaluation of derived analogues of selected small molecule non-peptidic inhibitors against serotype BoNT/ F. <i>Toxicon</i> , 2023, 222, 106981.	1.6	0

#	ARTICLE	IF	CITATIONS
397	Botulism in Spain: Epidemiology and Outcomes of Antitoxin Treatment, 1997â€“2019. <i>Toxins</i> , 2023, 15, 2.	3.4	2
398	Lambert-Eaton Myasthenic Syndrome and Botulism. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2022, 28, 1596-1614.	0.8	2
399	Child with Acute Limb Weakness. , 2022, , 683-698.		0
400	Infant Botulism, Israel, 2007â€“2021. <i>Emerging Infectious Diseases</i> , 2023, 29, 235-241.	4.3	5
401	Anti-virulence compounds against <i>Staphylococcus aureus</i> associated with bovine mastitis: A new therapeutic option?. <i>Microbiological Research</i> , 2023, 271, 127345.	5.3	5
402	Light Chain Role in Action of Botulinum Toxins/Clostridial Neurotoxins. , 2022, , 1145-1154.		0
403	Duration of Fecal Excretion of <i>Clostridium Botulinum</i> and Botulinum Neurotoxin in Patients Recovering from Infant Botulism. <i>Journal of Pediatrics</i> , 2023, 258, 113396.	1.8	0
404	Botulism in the 21st Century: A Scoping Review. , 2023, 2, .		1
405	Types of neuromuscular disease. , 2023, , 3-22.		0
406	A Three-Monoclonal Antibody Combination Potently Neutralizes BoNT/G Toxin in Mice. <i>Toxins</i> , 2023, 15, 316.	3.4	2
407	Pathogenicity and virulence of <i>Clostridium botulinum</i> . <i>Virulence</i> , 2023, 14, .	4.4	8
408	<i>Clostridium botulinum</i> Toxin (Botulism) Attack. , 2024, , 822-825.		0
410	Hyperimmune Globulins for the Management of Infectious Diseases. <i>Viruses</i> , 2023, 15, 1543.	3.3	0
412	Biodefense Vaccines, Vaccines for Emerging Infectious Diseases, and Coalition for Epidemic Preparedness Innovations (CEPI). , 2023, , 172-190.e9.		0
413	Passive Immunization. , 2023, , 100-112.e11.		0
414	<i>Clostridien</i> . , 2023, , 116-122.		0
416	Bacterial metalloproteases as promising drug targets for antivirulence agents. <i>Annual Reports in Medicinal Chemistry</i> , 2023, , .	0.9	0
417	Food Safety: Infectious Disease. , 2020, , .		0

#	ARTICLE	IF	CITATIONS
418	Newborn with Lethargy and Hypotonia. NeoReviews, 2023, 24, e733-e736.	0.8	0
419	Development and characterization of a novel neutralizing scFv vectored immunoprophylaxis against botulinum toxin type A. Journal of Drug Targeting, 2024, 32, 213-222.	4.4	0
420	From Rarity to Recognition: Infantile Botulism and the Broad Spectrum of Differential Diagnoses. Case Reports in Pediatrics, 2024, 2024, 1-3.	0.4	0